Barbituric Acid Or Derivative (including Thioanalogs) Patents (Class 514/270)
-
Patent number: 12084439Abstract: A compound of Chemical Formula 1, and an organic photoelectric device, an image sensor, and an electronic device including the same are disclosed: In Chemical Formula 1, each substituent is the same as defined in the detailed description.Type: GrantFiled: February 1, 2021Date of Patent: September 10, 2024Assignee: Samsung Electronics Co., Ltd.Inventors: Jisoo Shin, Chul Baik, Taejin Choi, Sung Young Yun, Kyung Bae Park, Gae Hwang Lee, Yeong Suk Choi, Chul Joon Heo
-
Patent number: 11814366Abstract: The present invention relates to compounds of formula (I), their use as medicaments, in particular as broad spectrum antiviral agents, their combination with a further antiviral agent and relative pharmaceutical compositions. In particular, the compounds of the invention are useful in the treatment of a disease caused by an enveloped virus.Type: GrantFiled: March 18, 2019Date of Patent: November 14, 2023Assignee: UNIVERSITA DEGLI STUDI DI SIENAInventors: Maurizio Botta, Filippo Canducci, Valeria Cagno, David Lembo, Cristina Tintori, Annalaura Brai, Nastasja Palombi
-
Patent number: 11414414Abstract: Provided are a pyrroloquinoline quinone glycine betaine salt and a crystalline form thereof. The pyrroloquinoline quinone glycine betaine salt has the advantages of high solubility, good stability, a simple preparation process and low solvent residue.Type: GrantFiled: February 6, 2018Date of Patent: August 16, 2022Assignee: SHANGHAI XUANCHUANG BIOLOGICAL TECHNOLOGY CO., LTD.Inventors: Guobin Ren, Jinyao Chen
-
Patent number: 11325901Abstract: Compounds and compositions are provided that can inhibit microsomal prostaglandin E synthase-1 (mPGES-1). The compounds and compositions can reduce inflammation in a subject, such as inflammation caused by an inflammation disorder or symptoms thereof. Pharmaceutical compositions comprising the compound are also provided. Furthermore, methods are provided for reducing inflammation and/or inhibiting mPGES-1. The methods can comprise administering an effective amount of the composition to a subject.Type: GrantFiled: June 28, 2017Date of Patent: May 10, 2022Assignee: University of Kentucky Research FoundationInventors: Chang-Guo Zhan, Fang Zheng, Kai Ding, Ziyuan Zhou
-
Patent number: 11311543Abstract: The present invention provides compositions and methods for inhibiting PTPN22 for restoring human central B-cell tolerance or for treating or preventing an autoimmune disease or disorder.Type: GrantFiled: May 26, 2017Date of Patent: April 26, 2022Assignee: Yale UniversityInventors: Eric Meffre, Jean-Nicolas Schickel
-
Patent number: 11220497Abstract: Compounds and compositions are provided that can inhibit microsomal prostaglandin E synthase-1 (mPGES-1). The compounds and compositions can reduce inflammation in a subject, such as inflammation caused by an inflammation disorder or symptoms thereof. Pharmaceutical compositions comprising the compound are also provided. Furthermore, methods are provided for reducing inflammation and/or inhibiting mPGES-1. The methods can comprise administering an effective amount of the composition to a subject.Type: GrantFiled: June 28, 2017Date of Patent: January 11, 2022Assignee: University of Kentucky Research FoundationInventors: Chang-Guo Zhan, Fang Zheng, Kai Ding, Ziyuan Zhou
-
Patent number: 11123344Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.Type: GrantFiled: October 15, 2020Date of Patent: September 21, 2021Assignee: AXSOME THERAPEUTICS, INC.Inventor: Herriot Tabuteau
-
Patent number: 11083694Abstract: Phenol formulations including phenol and an encapsulation agent, such as a cyclodextrin or derivatives thereof, and uses of such formulations.Type: GrantFiled: January 28, 2021Date of Patent: August 10, 2021Assignee: SAOL INTERNATIONAL DEVELOPMENT LTD.Inventors: Leonard O'Mahony, Sharon Hamm, John Devane, Imran Ahmed, David Penake
-
Patent number: 11072588Abstract: The present invention relates to bioactive cyclic compounds and their use as antimicrobial agents. In particular, the present invention relates to barbiturate mimics of Eusynstyelamides or small antimicrobial peptides. The compounds of the invention are represented by Formula (I).Type: GrantFiled: March 28, 2018Date of Patent: July 27, 2021Assignee: Universitetet i Tromsø—Norges Arktiske UniversitetInventors: Morten Bøhmer Strøm, Annette Bayer, Stig Olov Magnus Engqvist, Marianne Hagensen Paulsen, Dominik Ausbacher
-
Patent number: 11065248Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.Type: GrantFiled: September 23, 2020Date of Patent: July 20, 2021Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 10959962Abstract: Phenol formulations including phenol and an encapsulation agent, such as a cyclodextrin or derivatives thereof, and uses of such formulations.Type: GrantFiled: January 29, 2020Date of Patent: March 30, 2021Assignee: SAOL INTERNATIONAL DEVELOPMENT LTD.Inventors: Leonard O'Mahony, Sharon Hamm, John Devane, Imran Ahmed, David Penake
-
Patent number: 10767212Abstract: The present technology relates to kidney-type glutaminase (GLS) proteins that have a phenylalanine to tryptophan substitution at the position corresponding to residue 322 of human glutaminase C (GAC), and methods of using such proteins to screen for compounds that bind to the activation loop of GLS and/or modulate glutaminase activity of GLS.Type: GrantFiled: September 25, 2017Date of Patent: September 8, 2020Assignee: Cornell UniversityInventors: Richard Cerione, Jon W Erickson, Clint A Stalnecker
-
Patent number: 10092561Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.Type: GrantFiled: September 5, 2017Date of Patent: October 9, 2018Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9527820Abstract: The diethylammonium salts of phenyl-substituted thiobarbituric acid as anti-diabetic agents include compounds having the formula: wherein X is: and wherein R1 is selected from the group consisting of a hydrogen, halogen, methyl, trifluoromethyl, methoxy, and nitro, and R2 is either halogen or hydrogen, the R1 and R2 substituents being independently bonded to an ortho-, meta-, or para-carbon of the phenyl substituent.Type: GrantFiled: May 5, 2016Date of Patent: December 27, 2016Assignee: KING SAUD UNIVERSITYInventors: Assem Barakat, Mohamed Ali, Abdullah Mohammed Al Majid, Sammer Yousuf, Muhammad Iqbal Choudhary
-
Patent number: 9486450Abstract: This disclosure relates to methods administering hydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and hydroxybupropion or a prodrug of hydroxybupropion are also disclosed.Type: GrantFiled: February 9, 2015Date of Patent: November 8, 2016Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9474731Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.Type: GrantFiled: June 14, 2016Date of Patent: October 25, 2016Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9428467Abstract: The present invention relates to compositions and methods for the treatment and/or prevention of neurodegenerative disorders, e.g., Parkinson's disease (PD). In particular, the present invention provides compositions comprising selective antagonists of calcium ion channels (e.g., cav1.3-type ion channels), and methods of use thereof to treat or prevent neurodegenerative disorders.Type: GrantFiled: January 19, 2012Date of Patent: August 30, 2016Assignee: NORTHWESTERN UNIVERSITYInventors: Dalton J. Surmeier, Jr., Richard B. Silverman, Soosung Kang, Garry Cooper
-
Patent number: 9402844Abstract: This disclosure relates to methods administering erythrohydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being.Type: GrantFiled: February 20, 2015Date of Patent: August 2, 2016Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9370500Abstract: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.Type: GrantFiled: February 21, 2012Date of Patent: June 21, 2016Assignee: Centrexion Therapeutics CorporationInventors: James N. Campbell, Arthur F. Michaelis
-
Patent number: 9238032Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.Type: GrantFiled: November 26, 2014Date of Patent: January 19, 2016Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9198905Abstract: This disclosure relates to methods of decreasing dextrorphan plasma levels comprising co-administering hydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being in need of treatment with dextromethorphan. Dosage forms, drug delivery systems, and methods related to dextromethorphan and hydroxybupropion or a prodrug of bupropion are also disclosed.Type: GrantFiled: November 21, 2014Date of Patent: December 1, 2015Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9040508Abstract: The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.Type: GrantFiled: December 8, 2009Date of Patent: May 26, 2015Assignee: VM Pharma LLCInventors: Jay Jie-Qiang Wu, Ling Wang
-
Publication number: 20150141357Abstract: The present invention relates to methods of inhibiting shikimate pathway, comprising administering to a subject a pharmaceutically acceptable composition comprising a compound having a formula: or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: January 10, 2014Publication date: May 21, 2015Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Wen-Ching Wang, Shih-Ching Chou, Ming-Hua Hsu
-
Publication number: 20150140127Abstract: Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination thereof; b) comparing the level of the TJ protein in the test sample to the level of the TJ protein in a control sample, wherein an elevated level of the TJ protein in the test sample relative to the level of the TJ protein in the control sample indicates that the subject has an injury to the brain.Type: ApplicationFiled: June 25, 2013Publication date: May 21, 2015Applicant: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Servio H. Ramirez, Slava Rom, Yuri Persidsky
-
Publication number: 20150118302Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.Type: ApplicationFiled: October 29, 2014Publication date: April 30, 2015Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
-
Publication number: 20150118300Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.Type: ApplicationFiled: July 17, 2014Publication date: April 30, 2015Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
-
Publication number: 20140296270Abstract: Small molecule inhibitors of Stat3 and their derivatives are disclosed. Also described are methods to inhibit cell growth by use of Stat3 inhibitors, and the use of Stat3 inhibitors for the prevention and/or treatment of cancer. Further, inhibitors of Stat3 that also do not inhibit Stat1 are described as well as their derivatives. Methods of screening additional compounds for Stat3 inhibition activity and/or non-inhibition of Stat1 activity are also described herein.Type: ApplicationFiled: April 15, 2014Publication date: October 2, 2014Applicant: Baylor College of MedicineInventors: David J. Tweardy, Xuejun Xu, Moses M. Kasembeli
-
Patent number: 8841302Abstract: The present invention is directed to a combination product for treating or ameliorating hepatitis C virus (HCV) infection or disorders or symptoms associated therewith in a subject in need thereof comprising, a HCV inhibitor and one or more therapeutic agents selected from either or both a HCV protease inhibitor and one or more different therapeutic agents administered in combination in an effective amount to the subject.Type: GrantFiled: April 5, 2010Date of Patent: September 23, 2014Assignee: PTC Therapeutics, Inc.Inventors: Frederick C. Lahser, Zhengxian Gu
-
Publication number: 20140275134Abstract: The disclosed subject matter provides certain N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or development of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.Type: ApplicationFiled: October 16, 2012Publication date: September 18, 2014Inventors: John P. Toscano, Daryl A. Guthrie
-
Publication number: 20140242063Abstract: The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder.Type: ApplicationFiled: October 10, 2013Publication date: August 28, 2014Applicant: VALEANT LABORATORIES INTERNATIONAL BERMUDAInventors: Andrew John DUFFIELD, Graham JACKSON, Steven E. FRISBEE
-
Patent number: 8784892Abstract: The present invention is directed to the use of an agent selected from ethyl alcohol, isopropyl alcohol or a mixture thereof and a topically acceptable polymeric carrier in the preparation of a composition for the treatment of burns.Type: GrantFiled: July 7, 2010Date of Patent: July 22, 2014Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventor: Elka Touitou
-
Patent number: 8741914Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.Type: GrantFiled: March 25, 2010Date of Patent: June 3, 2014Assignee: AbbVie Inc.Inventors: Todd W. Rockway, David A. Betebenner, David A. DeGoey, Charles A. Flentge, Douglas K. Hutchinson, Warren M. Kati, Allan C. Krueger, Dachun Liu, Kenton L. Longenecker, John K. Pratt, Kent D. Stewart, Rolf Wagner, Clarence J. Maring
-
Patent number: 8680107Abstract: The invention presents methods of identifying small molecule compounds that are activators of tumor suppressor protein p53 pathway, and its associated family members p63 and p73, function. The invention is further drawn to methods of killing tumor cells and treating cancers or other conditions requiring activation of the p53 family member pathways and DNA damage response pathways with the small molecules.Type: GrantFiled: June 19, 2008Date of Patent: March 25, 2014Assignee: The Johns Hopkins UniversityInventors: Marikki Laiho, Karita Peltonen
-
Publication number: 20140073639Abstract: The application describes targets and methods that can inhibit bacterial growth in Gram-positive and Gram-negative bacteria. A bacterial enzyme, 2-epimerase, is common to both Gram-positive and Gram-negative bacteria and contains an allosteric site that can be targeted to disrupt the enzyme. The allosteric site is present on the bacterial 2-epimerase, but the analogous mammalian enzyme does not contain the allosteric site, providing a route for attacking bacterial infections without affecting the mammalian enzyme.Type: ApplicationFiled: August 8, 2013Publication date: March 13, 2014Applicants: The Rockefeller University, Avacyn Pharmaceuticals, Inc.Inventors: Vincent A. FISCHETTI, Allan R. GOLDBERG, Raymond SCHUCH
-
Publication number: 20140030249Abstract: The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder.Type: ApplicationFiled: September 27, 2013Publication date: January 30, 2014Applicant: Valeant International BermudaInventors: Andrew John DUFFIELD, Graham Jackson, Steven E. Frisbee, Okponanabofa Eradiri, John CK Lai
-
Publication number: 20130252983Abstract: A method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting activating phosphorylation of glutaminase C under conditions effective to reduce production of glutamate from glutamine. Methods for treating or preventing a condition mediated by the activating phosphorylation of glutaminase C, detecting a condition mediated by the activating phosphorylation of glutaminase C, and screening for compounds capable of treating or preventing cancer are also disclosed.Type: ApplicationFiled: September 12, 2011Publication date: September 26, 2013Applicant: CORNELL UNIVERSITYInventors: Kristin Wilson Cerione, Richard A. Cerione
-
Publication number: 20130217685Abstract: The invention relates to compositions and methods for inhibiting RNA binding proteins (e.g., MEX-3, MEX-5 and POS-1), as well as methods for treating and preventing disorders associated with parasitic infections and inflammatory disorders.Type: ApplicationFiled: January 8, 2013Publication date: August 22, 2013Applicant: UNIVERSITY OF MASSACHUSETTSInventor: University of Massachusetts
-
Patent number: 8466129Abstract: The present invention relates to methods of preventing airway remodeling using A2B adenosine receptor antagonists. This invention finds utility in the treatment and prevention of asthma, COPD, pulmonary fibrosis, emphysema, and other pulmonary diseases. The invention also relates to pharmaceutical compositions for use in the method.Type: GrantFiled: October 26, 2009Date of Patent: June 18, 2013Assignee: Gilead Sciences, Inc.Inventors: Dewan Zeng, Michael R. Blackburn, Luiz Belardinelli
-
Publication number: 20130071353Abstract: Inhibitors of retroviral propagation, methods of treatment and prevention of retroviral infections using the inhibitors, and pharmaceutical compositions including the inhibitors, are disclosed.Type: ApplicationFiled: March 14, 2011Publication date: March 21, 2013Applicant: TRANA DISCOVERY, INCInventors: Richard H. Guenther, Jerzy R. Szewczyk
-
Patent number: 8314115Abstract: A method of treating movement disorders comprises administering to a human or animal subject in need of treatment a therapeutically effective amount of at least one compound according to the following formula: wherein R3 and R4 are each independently selected from the group consisting of lower alkyl, phenyl and lower alkyl substituted phenyl, and R1 and R2 are each independently either a hydrogen atom or a radical of the formula wherein R5 and R6 are each independently selected from the group consisting of H, lower alkyl, phenyl and lower alkyl substituted phenyl, its pharmaceutically acceptable salts, prodrugs or metabolites thereof.Type: GrantFiled: December 15, 2009Date of Patent: November 20, 2012Assignee: Taro Pharmaceutical Industries LimitedInventor: Daniel A. Moros
-
Patent number: 8304421Abstract: Indole derivatives that are useful in the treatment of cancer as a chemotherapeutic agent or radiosensitizing agent.Type: GrantFiled: September 30, 2009Date of Patent: November 6, 2012Assignees: Vanderbilt University, University of Kentucky Research FoundationInventors: Peter A. Crooks, Thirupathi R. Yerramreddy, Narsimha R. Penthala, Michael L. Freeman, Sekhar R. Konjeti
-
Publication number: 20120245118Abstract: Methods of treating stuttering include treating people with gamma-aminobutyric acid (GABA) receptor modulators, including cyclopyrrolones. A second active agent may be used with GABA receptor modulators. Active enantiomers, active metabolites, and pharmaceutically acceptable salts of gamma-aminobutyric acid receptor modulators, including cyclopyrrolones, are acceptable components of the compositions. The cyclopyrrolone class of modulators includes pagoclone, suriclone, zopiclone, 2-(7-chloro-2-naphthyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindolin-1-one, 2-(7-chloro-2-naphthyridin-1,8-yl)isoindolin-1-yl-4-acetamidobutyrate, and 2-(7-chloro-1,8-naphthyridin-2yl)-3-(5-methyl-5-hydroxy-2-oxohexyl)-1-isoindolinone.Type: ApplicationFiled: June 6, 2012Publication date: September 27, 2012Applicant: Endo Pharmaceuticals Solutions Inc.Inventors: John J. Murphy, Kay Jorgenson D'Orlando
-
Publication number: 20120220610Abstract: The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the cell or tissue under conditions effective to reduce production of glutamate from glutamine. Compounds for carrying out this method are also disclosed.Type: ApplicationFiled: March 25, 2010Publication date: August 30, 2012Applicant: CORNELL UNIVERSITYInventors: Richard A. Cerione, Jon W. Erickson, Kristin Wilson Cerione, Jianbin Wang
-
Publication number: 20120196883Abstract: The present invention relates to compositions and methods for the treatment and/or prevention of neurodegenerative disorders, e.g., Parkinson's disease (PD). In particular, the present invention provides compositions comprising selective antagonists of calcium ion channels (e.g., cav1.3-type ion channels), and methods of use thereof to treat or prevent neurodegenerative disorders.Type: ApplicationFiled: January 19, 2012Publication date: August 2, 2012Inventors: Dalton J. Surmeier, JR., Richard B. Silverman, Soosung Kang, Garry Cooper
-
Publication number: 20120178749Abstract: The present invention generally relates to compounds to treat viral infections and methods of their use. In particular, compounds of the present invention inhibit the activity of NS1 protein, thereby mitigating viral infection and, in particular, influenza virus infection. Accordingly, NS1 protein inhibitors and methods of treatment that employ such inhibitors are contemplated by the present invention.Type: ApplicationFiled: February 21, 2012Publication date: July 12, 2012Inventors: Michael Roth, Beatriz Fontoura, Shuguang Wei, Neal Satterly
-
Publication number: 20120157483Abstract: The invention relates to medicine, in particular to gastroenterology, and lies in the field of treatment of liver diseases of various origins. For this purpose, the hepatoprotective agent that is introduced to the patient is embodied as derivatives of bis(2-thio-4,6-dioxo-1,2,3,4,5,6-hexahydropyrimidine-5-yl)arylmethanes: The method provides reduction of the manifestations of cytolysis under the influence of damaging agents and a statistically significant reduction of dysproteinemia, it accelerates restoration of detoxifying processes of the liver, increases induction of endogenic interferon alfa and, consequently, makes the protection of liver cells during hepatitides of various origins more effective.Type: ApplicationFiled: June 4, 2010Publication date: June 21, 2012Inventors: Georgy Viktorovich Tets, Viktor Veniaminovich
-
Publication number: 20120135089Abstract: The present invention provides, e.g., compounds having the structure of formula (I): The present invention also provides pharmaceutical compositions that include such compounds, and methods for modulating murine double minute 2 protein (Mdm2) E3 ligase activity, particularly the Mdm2-MdmX hetero-complex E3 ligase activity, using such compounds.Type: ApplicationFiled: March 17, 2010Publication date: May 31, 2012Inventors: Brent R. Stockwell, Ariel Herman
-
Patent number: 8158639Abstract: Methods of providing neuroprotection are disclosed comprising administering a non-sedative barbiturate compound in an amount sufficient to achieve neuroprotection in a mammalian subject. Preferred compounds are in the family of diphenylbarbituric acid and analogs. Preferred doses for a neuroprotective effect exceed the dosage of a corresponding sedative barbiturate without sedative side-effects such as anesthesia and death.Type: GrantFiled: April 13, 2010Date of Patent: April 17, 2012Assignee: Taro Pharmaceutical Industries Ltd.Inventors: Daniel A. Moros, Barrie Levitt, Avraham Yacobi
-
Patent number: 8138166Abstract: The present invention discloses a method to induce fatty liver in an animal. The steps of the method comprise: feeding an animal with a high calorie diet, and injecting a mitochondrial inhibitor into the animal to inhibit the mitochondrial activity of the animal, then resulting in fat accumulation and inflammation in the liver of the animal.Type: GrantFiled: July 8, 2010Date of Patent: March 20, 2012Assignee: Taipei Medical UniversityInventors: Rong-Hong Hsieh, Sheng-Mei Lin
-
Patent number: 8138197Abstract: The invention relates to a compound of a general formula (I): wherein Ar1 represents a group formed from an aromatic ring selected from a group consisting of benzene, pyrazole, isoxazole, pyridine, indole, 1H-indazole, 1H-furo[2,3-c]pyrazole, 1H-thieno[2,3-c]pyrazole, benzimidazole, 1,2-benzisoxazole, imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine and 1H-pyrazolo[3,4-a]pyridine, having Ar2, and optionally having one or two or more substituents selected from R3; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; or a C1-C6 alkyl group optionally having a substituent; or an aryl or heterocyclic group optionally having a substituent; or a C1-C6 alkyl group or a C2-C6 alkenyl group having the aryl or heterocyclic group; T and U each independently represent a nType: GrantFiled: January 8, 2008Date of Patent: March 20, 2012Assignees: MSD K.K., Merck Sharp & Dohme Corp.Inventors: Tomoharu Iino, Hideki Jona, Hideki Kurihara, Masayuki Nakamura, Kenji Niiyama, Jun Shibata, Tadashi Shimamura, Hitomi Watanabe, Takeru Yamakawa, Lihu Yang